acrivastine-pseudoephedrine oral brand names and other generic formulations include:
iobenguane sulfate i-123 iv brand names and other generic formulations include:
acrivastine-pseudoephedrine oral and iobenguane sulfate i-123 iv
acrivastine-pseudoephedrine oral decreases effects of iobenguane sulfate i-123 iv by the drugs competing for binding to the location in the body that is targeted by these drugs. Combination may cause false-negative imaging results.
acrivastine-pseudoephedrine oral and iobenguane sulfate i-123 iv
acrivastine-pseudoephedrine oral decreases effects of iobenguane sulfate i-123 iv by receptor binding competition. If clinically appropriate, discontinue drugs that compete for NE receptor sites for at least 5 half-lives; may cause false-negative imaging results. Do not administer pseudoephedrine until at least 7 days after each iobenguane dose.
Check for more interactions with the Drug Interaction Checker
Drug Interaction Categories
Contraindicated
Never use this combination of drugs because of high risk for dangerous interaction
Serious
Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed
Significant
Potential for significant interaction (monitoring by your doctor is likely required)
Minor
Interaction is unlikely, minor, or nonsignificant